Azenta (AZTA)
Market Price (6/26/2026): $24.63 | Market Cap: $1.1 BilSector: Health Care | Industry: Life Sciences Tools & Services
Azenta (AZTA)
Market Price (6/26/2026): $24.63Market Cap: $1.1 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% Stock buyback supportStock Buyback 3Y Total is 1.0 Bil Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -114% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% Key risksAZTA key risks include a [1] material weakness in its internal control over financial reporting. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 10% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -26% |
| Stock buyback supportStock Buyback 3Y Total is 1.0 Bil |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Automation & Robotics. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -91%, 3Y Excs Rtn is -114% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.3% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% |
| Key risksAZTA key risks include a [1] material weakness in its internal control over financial reporting. |
Qualitative Assessment
AI Analysis | Feedback
Azenta (AZTA) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Weaker-than-expected fiscal Q2 2026 financial results, characterized by a significant organic revenue decline and a substantial goodwill impairment charge.
Azenta reported its fiscal second quarter 2026 (ended March 31, 2026) results on May 5, 2026, revealing that total reported revenue grew by only 1% year-over-year to $145 million, while organic revenue notably declined by 3%. This organic revenue drop was attributed to lower performance in its Multiomics and Sample Management Solutions segments, impacted by weakened demand in North America and competitive pressures. Furthermore, the company incurred a GAAP operating loss of $165.8 million, primarily driven by a $149.1 million non-cash goodwill impairment charge related to these segments. Adjusted EBITDA margin also fell to 5.4%, a decrease of 300 basis points year-over-year and below expectations.
2. Material reduction in full-year fiscal 2026 guidance, significantly lowering revenue and profitability expectations.
Following the disappointing fiscal Q2 2026 results, Azenta dramatically cut its financial outlook for the fiscal year ending September 30, 2026. Previously, the company had projected organic revenue growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion for fiscal 2026. The updated guidance now anticipates total reported revenue from continuing operations to range between $603 million and $621 million, with organic revenue expected to range from a decline of approximately 2% to a growth of 1% relative to fiscal 2025. Adjusted EBITDA margin is now expected to be flat to down approximately 125 basis points. Additionally, free cash flow growth expectations were lowered from 30% to 10-15% year-over-year.
Show more
Azenta (AZTA) stock has lost about 10% since 2/28/2026 because of the following key factors:
1. Weaker-than-expected fiscal Q2 2026 financial results, characterized by a significant organic revenue decline and a substantial goodwill impairment charge.
Azenta reported its fiscal second quarter 2026 (ended March 31, 2026) results on May 5, 2026, revealing that total reported revenue grew by only 1% year-over-year to $145 million, while organic revenue notably declined by 3%. This organic revenue drop was attributed to lower performance in its Multiomics and Sample Management Solutions segments, impacted by weakened demand in North America and competitive pressures. Furthermore, the company incurred a GAAP operating loss of $165.8 million, primarily driven by a $149.1 million non-cash goodwill impairment charge related to these segments. Adjusted EBITDA margin also fell to 5.4%, a decrease of 300 basis points year-over-year and below expectations.
2. Material reduction in full-year fiscal 2026 guidance, significantly lowering revenue and profitability expectations.
Following the disappointing fiscal Q2 2026 results, Azenta dramatically cut its financial outlook for the fiscal year ending September 30, 2026. Previously, the company had projected organic revenue growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion for fiscal 2026. The updated guidance now anticipates total reported revenue from continuing operations to range between $603 million and $621 million, with organic revenue expected to range from a decline of approximately 2% to a growth of 1% relative to fiscal 2025. Adjusted EBITDA margin is now expected to be flat to down approximately 125 basis points. Additionally, free cash flow growth expectations were lowered from 30% to 10-15% year-over-year.
3. Persistent operational challenges and a delayed strategic asset sale contributed to investor uncertainty.
The company continued to face softness in its automated and cryogenic store systems, with ongoing quality remediation delays that are projected to extend into fiscal Q3 2026. Compounding these operational hurdles, the planned sale of its B Medical Systems business for $63 million was delayed as of the end of fiscal Q2 2026 due to the buyer's financing issues. These challenges underscore execution risks and operational inefficiencies, contributing to a cautious outlook from investors and analysts alike.
4. Initiation of securities fraud investigations by multiple law firms citing discrepancies between prior guidance and reported results.
In the wake of Azenta's fiscal Q2 2026 earnings report and the substantial reduction in fiscal 2026 guidance, several law firms launched investigations into potential securities fraud. These investigations highlight the significant disparity between the optimistic outlook and reaffirmed guidance provided by management in February 2026 (projecting strong organic revenue growth and EBITDA margin expansion) and the subsequent reported results in May 2026, which included a large goodwill impairment charge and dramatically lowered future expectations. This discrepancy has led to concerns about potential misrepresentation and has negatively impacted shareholder confidence.
Show less
Stock Movement Drivers
Fundamental Drivers
The -8.7% change in AZTA stock from 2/28/2026 to 6/25/2026 was primarily driven by a -8.7% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.98 | 24.63 | -8.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 595 | 596 | 0.2% |
| P/S Multiple | 2.1 | 1.9 | -8.7% |
| Shares Outstanding (Mil) | 46 | 46 | -0.3% |
| Cumulative Contribution | -8.7% |
Market Drivers
2/28/2026 to 6/25/2026| Return | Correlation | |
|---|---|---|
| AZTA | -8.7% | |
| Market (SPY) | 7.3% | 21.7% |
| Sector (XLV) | -2.5% | 20.7% |
Fundamental Drivers
The -30.7% change in AZTA stock from 11/30/2025 to 6/25/2026 was primarily driven by a -31.5% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 35.56 | 24.63 | -30.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 586 | 596 | 1.8% |
| P/S Multiple | 2.8 | 1.9 | -31.5% |
| Shares Outstanding (Mil) | 46 | 46 | -0.6% |
| Cumulative Contribution | -30.7% |
Market Drivers
11/30/2025 to 6/25/2026| Return | Correlation | |
|---|---|---|
| AZTA | -30.7% | |
| Market (SPY) | 8.1% | 27.7% |
| Sector (XLV) | -0.5% | 13.0% |
Fundamental Drivers
The -7.8% change in AZTA stock from 5/31/2025 to 6/25/2026 was primarily driven by a -8.7% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.72 | 24.63 | -7.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 586 | 596 | 1.7% |
| P/S Multiple | 2.1 | 1.9 | -8.7% |
| Shares Outstanding (Mil) | 46 | 46 | -0.7% |
| Cumulative Contribution | -7.8% |
Market Drivers
5/31/2025 to 6/25/2026| Return | Correlation | |
|---|---|---|
| AZTA | -7.8% | |
| Market (SPY) | 26.0% | 34.0% |
| Sector (XLV) | 19.4% | 29.4% |
Fundamental Drivers
The -43.1% change in AZTA stock from 5/31/2023 to 6/25/2026 was primarily driven by a -62.0% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6252026 | Change |
|---|---|---|---|
| Stock Price ($) | 43.25 | 24.63 | -43.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 597 | 596 | -0.1% |
| P/S Multiple | 5.0 | 1.9 | -62.0% |
| Shares Outstanding (Mil) | 69 | 46 | 50.0% |
| Cumulative Contribution | -43.1% |
Market Drivers
5/31/2023 to 6/25/2026| Return | Correlation | |
|---|---|---|
| AZTA | -43.1% | |
| Market (SPY) | 82.6% | 39.1% |
| Sector (XLV) | 28.0% | 34.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AZTA Return | 53% | -44% | 12% | -23% | -33% | -28% | -65% |
| Peers Return | 37% | -23% | -9% | -1% | 5% | 1% | 1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| AZTA Win Rate | 50% | 33% | 50% | 42% | 50% | 50% | |
| Peers Win Rate | 78% | 35% | 43% | 48% | 52% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AZTA Max Drawdown | -28% | -63% | -41% | -40% | -54% | -61% | |
| Peers Max Drawdown | -18% | -35% | -35% | -21% | -34% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, ILMN, A, LH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/25/2026 (YTD)
How Low Can It Go
| Event | AZTA | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -19.2% | -6.7% |
| % Gain to Breakeven | 23.7% | 7.1% |
| Time to Breakeven | 28 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -44.8% | -33.7% |
| % Gain to Breakeven | 81.2% | 50.9% |
| Time to Breakeven | 42 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -34.0% | -19.2% |
| % Gain to Breakeven | 51.4% | 23.8% |
| Time to Breakeven | 127 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -21.0% | -12.2% |
| % Gain to Breakeven | 26.6% | 13.9% |
| Time to Breakeven | 106 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -21.2% | -6.8% |
| % Gain to Breakeven | 26.8% | 7.3% |
| Time to Breakeven | 106 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -29.6% | -17.9% |
| % Gain to Breakeven | 42.0% | 21.8% |
| Time to Breakeven | 24 days | 123 days |
In The Past
Azenta's stock fell -0.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AZTA | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -44.8% | -33.7% |
| % Gain to Breakeven | 81.2% | 50.9% |
| Time to Breakeven | 42 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -34.0% | -19.2% |
| % Gain to Breakeven | 51.4% | 23.8% |
| Time to Breakeven | 127 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -21.0% | -12.2% |
| % Gain to Breakeven | 26.6% | 13.9% |
| Time to Breakeven | 106 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -21.2% | -6.8% |
| % Gain to Breakeven | 26.8% | 7.3% |
| Time to Breakeven | 106 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -29.6% | -17.9% |
| % Gain to Breakeven | 42.0% | 21.8% |
| Time to Breakeven | 24 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -32.7% | -15.4% |
| % Gain to Breakeven | 48.6% | 18.2% |
| Time to Breakeven | 218 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -80.9% | -53.4% |
| % Gain to Breakeven | 423.2% | 114.4% |
| Time to Breakeven | 833 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -25.0% | -8.6% |
| % Gain to Breakeven | 33.3% | 9.5% |
| Time to Breakeven | 3366 days | 47 days |
In The Past
Azenta's stock fell -0.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Azenta (AZTA)
Azenta, Inc. (AZTA) operates as a global technology company with two distinct but complementary business areas. It provides advanced manufacturing automation solutions crucial for the semiconductor industry, alongside a comprehensive suite of sample-based services and solutions tailored for the life sciences market. The company structures its offerings into two main segments: Life Sciences Products and Life Sciences Services.
Within its Life Sciences segments, Azenta offers a diverse portfolio. The Life Sciences Products segment focuses on automated ultra-cold storage systems and related consumables like tubes and racks, along with instruments for managing samples, such as labeling and capping devices. The Life Sciences Services segment delivers genomic services and extensive sample repository solutions, encompassing secure on-site and off-site storage, cold chain logistics, sample transport, and disaster recovery. This segment also provides informatics solutions, offering software for laboratory workflow management, sample inventory, and environmental monitoring. These life science offerings primarily serve the pharmaceutical, biotechnology, and academic research sectors.
While deeply involved in life sciences, Azenta also maintains a significant presence in the semiconductor sector, providing specialized automation solutions essential for manufacturing processes. In essence, Azenta enables industries to efficiently manage, automate, and protect critical biological samples and data, while also contributing vital automation expertise to semiconductor fabrication globally.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Azenta:
- Like **Applied Materials** for semiconductor manufacturing automation.
- The **Amazon Web Services (AWS)** for managing physical and digital assets in high-tech life science labs.
AI Analysis | Feedback
- Automated Ultra-Cold Storage Systems: Advanced systems designed for the precise and secure ultra-cold storage of biological samples.
- Life Sciences Consumables: Essential items like racks, tubes, caps, plates, and foils used in sample management and storage.
- Life Sciences Instruments: Devices for automating tasks such as labeling, capping, de-capping, and auditing of tubes and plates.
- Genomic Services: Specialized services focused on genomic analysis and related solutions for the life sciences market.
- Sample Repository Solutions: Comprehensive services including sample storage (on-site and off-site), cold chain logistics, and biospecimen procurement.
- Sample Intelligence Software (Informatics): Software solutions that support laboratory workflow scheduling, sample inventory, logistics, and data management for life science operations.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
John Marotta, President & Chief Executive Officer
Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He brings two decades of experience leading global companies in life sciences, medical devices, and diagnostics. Prior to Azenta, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. He previously held the roles of CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company, where he oversaw its global revenue growth and led its IPO from owners KKR Capital. He also held various senior executive positions at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, Inc., where he was involved in significant value-creating transactions.
Lawrence Lin, Executive Vice President & Chief Financial Officer
Mr. Lin joined Azenta in November 2024 as Executive Vice President and Chief Financial Officer, bringing over twenty years of finance experience. Before joining Azenta, Mr. Lin was Chief Financial Officer at GeoStabilization International LLC, a privately held industrial company. He also served as Senior Vice President of Finance Operations at PHC Holdings Corporation. His prior roles include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, a global medical technology company, and Vice President of Finance Operations at KaVo Kerr, which was part of Danaher before being spun off as Envista.
Dr. Ginger Zhou, Senior Vice President, President GENEWIZ
Dr. Zhou serves as the Senior Vice President and President of GENEWIZ, an Azenta Life Sciences brand.
Olga Pirogova, Senior Vice President & Chief Human Resources Officer
Mrs. Pirogova joined Azenta Life Sciences in August 2023. She is responsible for developing and executing Azenta's human resources strategy. Prior to Azenta, Ms. Pirogova served as CHRO at Speedcast, a global satellite communications service provider.
Ephraim Starr, Senior Vice President, General Counsel & Corporate Secretary
Mr. Starr holds the position of Senior Vice President, General Counsel & Corporate Secretary at Azenta Life Sciences.
AI Analysis | Feedback
- Exposure to Semiconductor Industry Cyclicality: Azenta provides manufacturing automation solutions for the semiconductor industry. This sector is known for its cyclical nature and sensitivity to global economic conditions, which can lead to fluctuations in demand for Azenta's automation products and services.
- Intense Competition and Rapid Technological Change in Life Sciences: Azenta operates in the highly competitive life sciences market, offering products like automated storage systems and services such as genomics and sample management. The need to continually innovate and adapt to rapid technological advancements and evolving customer needs, coupled with competition from established players and new entrants, poses a significant risk to market share and profitability.
- Data Security, Privacy, and Regulatory Compliance in Sample Management: As a provider of sample repository solutions, cold chain logistics, biospecimen procurement, and sample intelligence software, Azenta handles sensitive biological samples and associated data. Risks include potential data breaches, non-compliance with evolving data privacy regulations (e.g., HIPAA, GDPR-like regulations), and the operational and reputational damage that could result from such incidents.
AI Analysis | Feedback
AI Analysis | Feedback
Azenta, Inc. (AZTA) operates primarily within the life sciences market, providing a range of products and services. The addressable markets for their main offerings are detailed below:
- Genomic Services: The global genomics services market was valued at approximately USD 8.5 billion in 2024 and is projected to grow to around USD 25 billion by 2034, exhibiting a compound annual growth rate (CAGR) of over 11.5% from 2025 to 2034. North America is a significant region within this market, with the U.S. market alone valued at USD 4.3 billion in 2024 and expected to reach USD 9.6 billion by 2034.
- Sample Repository Solutions / Biobanking: The global biobanks market size was estimated at USD 86.82 billion in 2025 and is anticipated to reach USD 160.54 billion by 2033, growing at a CAGR of 8.11% from 2026 to 2033. Europe held the largest share of this market in 2025, while the biobank industry in the U.S. is expected to grow significantly.
- Automated Ultra-Cold Storage Systems: The global automated sample storage systems market, which includes automated ultra-cold storage, was valued at approximately USD 1.5 billion in 2024 and is projected to reach around USD 4.6 billion by 2034, with a CAGR of 11.8% during the forecast period from 2025 to 2034. North America led this market in 2024, holding over a 38.5% share. Automated ultra-cold storage at -80 °C accounted for 51.1% of the automated sample storage systems market in 2024.
- Laboratory Automation Instruments: The global laboratory automation market size was valued at USD 9.2 billion in 2025 and is projected to grow to USD 20.71 billion by 2034, exhibiting a CAGR of 9.43% during the forecast period. North America holds approximately 37% market share in the global laboratory automation market.
- Sample Intelligence Software Solutions (Informatics): The global laboratory sample management software market size was estimated at USD 1.85 billion in 2025 and is expected to reach USD 4.74 billion by 2032, with a CAGR of 14.38%.
AI Analysis | Feedback
Azenta (NASDAQ: AZTA) is expected to drive future revenue growth over the next two to three years through several key initiatives within its core life sciences segments.
One primary driver is the anticipated organic revenue growth in its core Sample Management Solutions (SMS) and Multiomics segments. The company has provided guidance for 3% to 5% organic revenue growth for fiscal years 2025 and 2026. This growth is expected to be fueled by mid-single-digit growth in Sample Management Solutions, driven by consumables, instruments, and clinical cryogenic stores, while the Multiomics segment is projected for low-single-digit growth, with Next-Generation Sequencing (NGS) services being a strong contributor.
Another significant driver is the expansion of its biorepository presence and services, both organically and through strategic mergers and acquisitions. Azenta plans to grow its biorepository footprint in Europe and the U.K. through M&A, exemplified by the acquisition of UK Biocentre. This expansion aims to scale automated biobanking operations and enhance the company's partnerships with government, academic, and pharmaceutical/biotech customers, leading to increased sample processing and storage volumes.
Furthermore, investments in new technologies and automated solutions, alongside the regionalization of gene synthesis, are expected to contribute to revenue growth. Azenta is focusing on regionalizing gene synthesis capabilities in the U.S. and Europe, partly due to BIOSECURE concerns. The company continues to invest in innovative technology and automated solutions, emphasizing its identity as an "automated solutions business" rather than solely a freezer business.
Finally, the company anticipates new product launches in 2027 and 2028, which will open up fresh avenues for revenue generation and sustain long-term growth.
AI Analysis | Feedback
Share Repurchases
- Azenta authorized a $250 million share repurchase program in December 2025, set to continue until December 31, 2028.
- In November 2022, the company authorized a $1.5 billion share repurchase program, with an intention to repurchase at least $1 billion in common stock over the subsequent year, including a $500 million accelerated share repurchase program.
Share Issuance
- Proceeds from the issuance of common stock were $2.77 million in fiscal year 2025.
- Proceeds from the issuance of common stock were $3.279 million in fiscal year 2024.
Outbound Investments
- Azenta acquired UK Biocentre Limited in March 2026 for GBP 20.5 million (net of cash and including contingent consideration), expanding its biorepository capabilities and establishing a European operational hub.
- The company divested its B Medical Systems business for $63 million in December 2025, with the sale expected to close by March 31, 2026, as part of a portfolio simplification strategy.
- In February 2023, Azenta acquired Ziath Ltd., a provider of 2D barcode readers for life sciences applications.
Capital Expenditures
- Capital expenditures totaled $34 million for the full fiscal year 2025.
- For the first quarter of fiscal year 2026 (ended December 31, 2025), capital expenditures were $6 million.
- The company's capital allocation strategy includes investing in high-value R&D, sales & marketing, and high-margin, high Return on Invested Capital (ROIC) parts of the business.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 185.23 |
| Mkt Cap | 32.7 |
| Rev LTM | 10,688 |
| Op Inc LTM | 1,563 |
| FCF LTM | 1,236 |
| FCF 3Y Avg | 1,170 |
| CFO LTM | 1,633 |
| CFO 3Y Avg | 1,593 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 1.0% |
| Rev Chg Q | 5.3% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 7.2% |
| Op Inc Chg 3Y Avg | 4.4% |
| Op Mgn LTM | 18.7% |
| Op Mgn 3Y Avg | 14.5% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 19.2% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 15.0% |
| FCF/Rev 3Y Avg | 16.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Sample Management Solutions | 325 | 319 | |||
| Multiomics | 269 | 255 | |||
| B Medical Systems | 83 | ||||
| Life Sciences Products | 305 | 199 | 200 | ||
| Life Sciences Services | 360 | 356 | 314 | ||
| Total | 594 | 656 | 665 | 555 | 514 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Sample Management Solutions | 28 | 11 | |||
| Impairment of intangible assets | 0 | -116 | |||
| Other miscellanous expenses | -0 | -0 | -0 | -14 | -26 |
| Merger and acquisition costs and costs related to share repurchase | -2 | -5 | -14 | ||
| Restructuring charges | -5 | -12 | -1 | -0 | |
| Amortization of completed technology | -8 | -25 | -7 | -8 | |
| Transformation and rebranding costs | -10 | -14 | |||
| Multiomics | -12 | -8 | |||
| Amortization of intangible assets other than completed technology | -16 | -26 | -28 | ||
| B Medical Systems | -6 | ||||
| Contingent consideration - fair value adjustments | 0 | 19 | |||
| Purchase accounting impact on inventory | 0 | ||||
| Life Sciences Products | -30 | 11 | 23 | ||
| Life Sciences Services | -15 | 11 | 23 | ||
| Restructuring and restructuring related charges | -5 | ||||
| Amortization of other intangible assets | -25 | -29 | |||
| Restructuring related charges | -13 | ||||
| Total | -27 | -201 | -73 | -25 | -31 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Sample Management Solutions | 854 | 859 | 676 | ||
| Cash and cash equivalents, restricted cash and marketable securities | 546 | 491 | 1,134 | 2,305 | 244 |
| Multiomics | 445 | 463 | 534 | ||
| Assets held for sale | 159 | 263 | 495 | ||
| General corporate assets | 54 | 24 | |||
| Deferred tax assets | 1 | 1 | 1 | 1 | 10 |
| B Medical Systems | 512 | ||||
| Other assets | 29 | 181 | 11 | ||
| Life Sciences Products | 379 | 279 | |||
| Life Sciences Services | 850 | 780 | |||
| Total | 2,060 | 2,100 | 2,886 | 3,716 | 1,820 |
Price Behavior
| Market Price | $24.63 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -39.9% | |
| 50 Days | 200 Days | |
| DMA Price | $22.20 | $28.53 |
| DMA Trend | down | down |
| Distance from DMA | 10.9% | -13.7% |
| 3M | 1YR | |
| Volatility | 76.4% | 63.4% |
| Downside Capture | 62.35 | 222.16 |
| Upside Capture | 84.73 | 144.34 |
| Correlation (SPY) | 17.2% | 33.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -3.07 | 0.40 | 1.27 | 1.64 | 1.90 | 1.36 |
| Up Beta | -12.16 | -0.61 | 0.23 | 0.49 | 1.27 | 1.21 |
| Down Beta | 2.74 | 1.53 | 2.70 | 2.47 | 2.16 | 1.45 |
| Up Capture | -141% | 66% | 61% | 102% | 210% | 128% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 13 | 25 | 34 | 63 | 125 | 365 |
| Down Capture | -196% | 119% | 184% | 212% | 175% | 111% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 7 | 16 | 29 | 60 | 123 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AZTA | |
|---|---|---|---|---|
| AZTA | -14.6% | 63.3% | 0.02 | - |
| Sector ETF (XLV) | 17.9% | 15.1% | 0.88 | 28.3% |
| Equity (SPY) | 22.1% | 12.4% | 1.33 | 33.4% |
| Gold (GLD) | 20.8% | 27.7% | 0.67 | 8.2% |
| Commodities (DBC) | 23.3% | 18.5% | 0.99 | 4.6% |
| Real Estate (VNQ) | 11.6% | 13.8% | 0.55 | 17.9% |
| Bitcoin (BTCUSD) | -42.9% | 42.5% | -1.20 | 18.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AZTA | |
|---|---|---|---|---|
| AZTA | -23.3% | 51.8% | -0.32 | - |
| Sector ETF (XLV) | 6.2% | 14.8% | 0.23 | 37.9% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 47.5% |
| Gold (GLD) | 17.4% | 18.3% | 0.77 | 6.9% |
| Commodities (DBC) | 7.9% | 19.5% | 0.30 | 10.4% |
| Real Estate (VNQ) | 2.8% | 18.9% | 0.05 | 37.8% |
| Bitcoin (BTCUSD) | 9.8% | 54.1% | 0.38 | 19.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AZTA | |
|---|---|---|---|---|
| AZTA | 9.1% | 51.4% | 0.37 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 41.7% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 52.6% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 5.8% |
| Commodities (DBC) | 5.9% | 18.0% | 0.25 | 15.5% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 37.8% |
| Bitcoin (BTCUSD) | 56.4% | 66.5% | 0.97 | 15.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/7/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | -25.3% | -28.8% | -7.2% |
| 2/4/2026 | -22.8% | -18.7% | -32.8% |
| 11/21/2025 | 16.3% | 16.2% | 15.7% |
| 8/5/2025 | -17.0% | -13.7% | -9.4% |
| 5/7/2025 | -0.6% | 9.8% | 11.3% |
| 2/5/2025 | 3.4% | -11.8% | -20.9% |
| 11/12/2024 | -3.2% | -11.0% | -0.1% |
| 8/6/2024 | -8.9% | -6.9% | -19.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 12 |
| # Negative | 14 | 14 | 13 |
| Median Positive | 12.1% | 16.2% | 11.0% |
| Median Negative | -7.0% | -9.7% | -9.4% |
| Max Positive | 21.8% | 22.3% | 32.4% |
| Max Negative | -25.3% | -28.8% | -32.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/5/2026 | -25.3% | -28.8% | -7.2% |
| 2/4/2026 | -22.8% | -18.7% | -32.8% |
| 11/21/2025 | 16.3% | 16.2% | 15.7% |
| 8/5/2025 | -17.0% | -13.7% | -9.4% |
| 5/7/2025 | -0.6% | 9.8% | 11.3% |
| 2/5/2025 | 3.4% | -11.8% | -20.9% |
| 11/12/2024 | -3.2% | -11.0% | -0.1% |
| 8/6/2024 | -8.9% | -6.9% | -19.0% |
| 5/8/2024 | -2.9% | -4.6% | -0.2% |
| 2/7/2024 | -1.6% | 0.9% | 0.5% |
| 11/13/2023 | 13.9% | 17.2% | 26.5% |
| 8/8/2023 | 20.3% | 18.7% | 9.7% |
| 5/9/2023 | -18.9% | -11.5% | 1.1% |
| 2/8/2023 | -18.3% | -16.8% | -27.5% |
| 11/14/2022 | 21.8% | 22.3% | 32.4% |
| 8/9/2022 | -3.1% | -2.8% | -17.7% |
| 5/9/2022 | 5.6% | 15.3% | 19.8% |
| 2/8/2022 | 3.8% | -1.5% | -8.5% |
| 11/18/2021 | -0.0% | -5.8% | -20.6% |
| 9/21/2021 | 0.6% | 1.1% | 2.2% |
| 8/5/2021 | -5.8% | -8.4% | -5.2% |
| 5/10/2021 | 2.8% | 1.5% | 7.7% |
| 2/2/2021 | -8.3% | -1.8% | -9.4% |
| 11/10/2020 | 12.1% | 19.0% | 22.7% |
| 7/30/2020 | 15.1% | 19.8% | 10.6% |
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 12 |
| # Negative | 14 | 14 | 13 |
| Median Positive | 12.1% | 16.2% | 11.0% |
| Median Negative | -7.0% | -9.7% | -9.4% |
| Max Positive | 21.8% | 22.3% | 32.4% |
| Max Negative | -25.3% | -28.8% | -32.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 12/04/2025 | 10-K |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/10/2025 | 10-Q |
| 09/30/2024 | 11/27/2024 | 10-K |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/21/2023 | 10-K |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/09/2023 | 10-Q |
| 09/30/2022 | 11/25/2022 | 10-K |
| 06/30/2022 | 08/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/05/2026 | 10-Q |
| 09/30/2025 | 12/04/2025 | 10-K |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/10/2025 | 10-Q |
| 09/30/2024 | 11/27/2024 | 10-K |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/21/2023 | 10-K |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/09/2023 | 10-Q |
| 09/30/2022 | 11/25/2022 | 10-K |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 02/09/2022 | 10-Q |
| 09/30/2021 | 11/24/2021 | 10-K |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 02/03/2021 | 10-Q |
| 09/30/2020 | 11/18/2020 | 10-K |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/01/2020 | 10-Q |
| 12/31/2019 | 02/06/2020 | 10-Q |
| 09/30/2019 | 12/17/2019 | 10-K |
| 06/30/2019 | 08/02/2019 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q2 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 603.00 Mil | 612.00 Mil | 621.00 Mil | ||||
| 2026 Organic Revenue Growth | -2.0% | -0.5% | 1.0% | -112.5% | -4.5% | Lowered | Guidance: 4.0% for 2026 |
| 2026 Free Cash Flow Growth | 10.0% | 12.5% | 15.0% | ||||
Prior: Q1 2026 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Organic Revenue Growth | 3.0% | 4.0% | 5.0% | 0.0% | 0.0% | Affirmed | Guidance: 4.0% for 2026 |
| 2026 Adjusted EBITDA Margin Expansion | 3.0% | 0.0% | 0.0% | Affirmed | Guidance: 3.0% for 2026 | ||
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.